| | Study id | Copeptin categories values | MetS and copeptin (high vs. low) | Mets and copeptin (Q2 vs. Q1) | Mets and copeptin (Q3 vs. Q1) | Mets and copeptin (Q4 vs. Q1) | Adjusted variables | | Odds ratio 95% confidence interval |
| | Saleem-2009 (AA) | Q1 (<5.0) | NE | 1.42 (1.05–1.93) | 1.49 (1.07–2.06) | 2.07 (1.45–2.95) | Age, sex, creatinine, smoking,statin or diuretic use, history of myocardial infarction/stroke, physical activity, and educational status | | Q2 (5.0–8.0) | | Q3 (8.0–12.7) | | Q4 (>12.7) | | Saleem-2009 (NHW) | Q1 (<3.3) | NE | 1.12 (0.79–1.59) | 1.79 (1.27–2.51) | 1.74 (1.21–2.50) | | Q2 (3.3–5.0) | | Q3 (5.0–7.9) | | Q4 (>7.9) |
| | Enhörning-2011 | Men: | NE | 1.55 (1.25–1.93) | 1.82 (1.47–2.25) | 1.93 (1.57–2.39) | None | | Q1 (<4.6) | | Q2 (4.6–7.1) | | Q3 (7.1–10.6) | | Q4 (10.7–4.3) | | Women: | | Q1 (<2.7) | | Q2 (2.7–4.2) | | Q3 (4.3–6.4) | | Q4 (6.5–14.3) |
| | Enhörning-2013 | NR | NE | 1.21 (0.85–1.72) | 1.05 (0.74–1.49) | 1.34 (0.95–1.91) | Follow-up time, age, sex, cystatin C, hypertension, glucose, triglycerides, HDL, and waist circumference |
| | Then-2015 (men) | NR | NE | NE | NE | 1.13 (0.72–1.76) | Age, history of myocardial infarction/stroke, smoking, alcohol intake, and physical activity | | Then-2015 (women) | NR | NE | NE | NE | 1.11 (0.68–1.83) |
| | Vintilă-2016 | Low (0.1–196.4) | 20 (3.03–131.7) | NE | NE | NE | None | | High (196.5–455.1) |
| | Canivell-2017 | NR | 1.12 (0.74–1.69) | NE | NE | NE | Age, sex, center, socioeconomic status, intake of fruits and vegetables, physical activity, alcohol intake, smoking, testosterone, and estradiol daytime urinary excretion |
| | Deligözoğlu-2020 | Q1 (<17.0) | NE | NE | 0.86 (0.22–3.28) | 0.33 (0.06–1.43) | None | | Q2 (17.0–26.4) | | Q3 (26.6–40.0) | | Q4 (40.3–95.0) |
|
|
AA: African-Americans, NHW: non-Hispanic Whites, MetS: metabolic syndrome, SD: standard deviation, NR: not reported, and NE: not evaluated. Significative values are in bold.
|
